Skip to content

Ketamine: all studies

Page 292 of 449: studies 2,911 to 2,920 of 4,483, newest first. Back to the ketamine overview

Research

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

American Journal of Psychiatry August 28, 2013 James W. Murrough, Dan V. Iosifescu, Lee C. Chang et al. 1,207 citations

OBJECTIVE: Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression. METHOD: This was a...

Ketamine alters oscillatory coupling in the hippocampus

Scientific Reports August 2, 2013 Fábio V. Caixeta, Alianda Maira Cornélio, Robson Scheffer-Teixeira et al. 134 citations

Recent studies show that higher order oscillatory interactions such as cross-frequency coupling are important for brain functions that are impaired in schizophrenia, including perception, attention and memory. Here we investigated the dynamics of oscillatory coupling in the hippocampus of awake rats upon NMDA receptor blockade by ketamine, a pharmacological model of schizophrenia. Ketamine (25,...

DOI: 10.1038/srep02348 (opens in new tab) Full text (opens in new tab) Ketamine Hippocampal formation Hippocampus Coupling piping +2

Ketamine as Antidepressant? Current State and Future Perspectives

Current Neuropharmacology August 1, 2013 Helge Hasselmann 36 citations

Major depressive disorder (MDD) is a serious mental disorder that ranks among the major causes of disease burden. Standard medical treatment targeting cerebral monoamines often provides only insufficient symptom relief and fails in approximately every fifth patient. The complexity of MDD therefore, reflects more than monoaminergic dysregulation. Initial research argues the case for excessive...

Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult Rats

Biological Psychiatry June 19, 2013 Eric M Parise, Lyonna F. Alcantara, Brandon L. Warren et al.

Background Major Depressive Disorder (MDD) afflicts up to 10% of adolescents. However, nearly 50% of those afflicted are considered non-responsive to available treatments. Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist has shown potential as a rapid-acting and long-lasting treatment for MDD in adults. Thus, the effectiveness and functional consequences of ketamine...

Ketamine Effects on Memory Reconsolidation Favor a Learning Model of Delusions

PLoS One June 12, 2013 Philip R. Corlett, Victoria C. Cambridge, Jennifer M. Gardner et al. 104 citations

Delusions are the persistent and often bizarre beliefs that characterise psychosis. Previous studies have suggested that their emergence may be explained by disturbances in prediction error-dependent learning. Here we set up complementary studies in order to examine whether such a disturbance also modulates memory reconsolidation and hence explains their remarkable persistence. First, we...

DOI: 10.1371/journal.pone.0065088 (opens in new tab) Memory consolidation Placebo Cognitive psychology Classical conditioning +5

From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine

CNS Neuroscience & Therapeutics June 1, 2013 Ornella Corazza, Sulaf Assi, Fabrizio Schifano 147 citations

This article reviews the recreational use of ketamine ("Special K"; KET) and explores the recent diffusion of its new derivative methoxetamine ("Special M"; MXE). The literature search on the nonclinical/recreational use of KET and MXE was carried out in a range of medical databases. Considering the limitations of peer-reviewed information, data were integrated with a qualitative assessment of...

Disruption of Frontal–Parietal Communication by Ketamine, Propofol, and Sevoflurane

Anesthesiology May 22, 2013 UnCheol Lee, Seungwoo Ku, Gyu‐jeong Noh et al. 436 citations

INTRODUCTION: Directional connectivity from anterior to posterior brain regions (or "feedback" connectivity) has been shown to be inhibited by propofol and sevoflurane. In this study the authors tested the hypothesis that ketamine would also inhibit cortical feedback connectivity in frontoparietal networks. METHODS: Surgical patients (n = 30) were recruited for induction of anesthesia with...

Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions

CNS Neuroscience & Therapeutics April 12, 2013 Giacomo Salvadore, Jaskaran Singh 80 citations

Several recent studies have shown that a single intravenous subanesthetic dose of ketamine, a NMDA receptor antagonist, exerts rapid antidepressant effects in patients with treatment refractory mood disorders and reduces suicidal ideation. Those insights have fueled tremendous excitement in the efforts to elucidate the mechanism underlying ketamine's antidepressant properties in animal models...

Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

CNS Neuroscience & Therapeutics April 10, 2013 G. Mion, Thierry Villevieille 690 citations

For more than 50 years, ketamine has proven to be a safe anesthetic drug with potent analgesic properties. The active enantiomer is S(+)-ketamine. Ketamine is mostly metabolized in norketamine, an active metabolite. During "dissociative anesthesia", sensory inputs may reach cortical receiving areas, but fail to be perceived in some association areas. Ketamine also enhances the descending...

DOI: 10.1111/cns.12099 (opens in new tab) Ketamine Nmda receptor Pharmacology Analgesic +8

Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Psychopharmacology March 1, 2013 Lawrence P Carter, Bethea A Kleykamp, Roland R. Griffiths et al. 19 citations

Several studies have documented impairments in memory processes as a result of ketamine administration; however, few studies have compared the profile of cognitive effects of ketamine to other drugs. The aim of this study was to compare the cognitive effects of ketamine with those of triazolam in healthy volunteers. Doses of ketamine (0.2, 0.4 mg/kg intramuscular (i.m.)), triazolam (0.2, 0.4...

DOI: 10.1007/s00213-012-2883-x (opens in new tab) Full text (opens in new tab) Cognitive impairment Memory impairment Cognitive dysfunction Mental decline +28